The acquisition strengthens Kazia's platform strategy with a novel, preclinical epigenetic program that could enable early partnerships. Traders should monitor progress toward IND filings and potential non-dilutive funding or collaboration deals, especially given the platform's broad applicability across tumor types.
Price Chart
Executive Summary
Kazia Therapeutics has in-licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer, expanding its oncology pipeline with a preclinical program aimed at overcoming immunotherapy resistance via chromatin-level regulation. The deal includes a $1.39 million upfront payment and a revenue-sharing structure, with $6 million expected to advance both this and its PD-L1 degrader program to IND readiness over 18 months.
Key Facts
- Kazia acquired global rights to QIMR Berghofer's SETDB1-targeted epigenetic platform, including lead candidate MSETC.
- The SETDB1 program targets immune resistance in cancer by reactivating suppressed immune signaling at the chromatin level.
- Upfront payment of $1,390,000 to QIMR Berghofer; no clinical or regulatory milestones, but tiered revenue sharing on commercialization.
- Combined cost to advance SETDB1 and PD-L1 degrader programs to IND-enabling stage is ~$6 million over 18 months, partially offset by Australian R&D tax incentives.
- Kazia's pipeline now spans three layers: chromatin-level (SETDB1), transcriptional (paxalisib), and protein-level (PD-L1 degrader NDL2).
Financial Impact
Approximately $1.39 million upfront cash outflow; total expected R&D spend of $6 million over 18 months for dual program advancement.
Risk Factors
- Preclinical stage: SETDB1 program is early and carries high risk of failure in translation to humans.
- Execution risk in advancing two preclinical programs in parallel despite projected efficiencies.
- Reliance on Australian R&D tax incentives, which may be delayed or reduced.
- Forward-looking statements dominate; no near-term catalysts or revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-043086 |
| Document: ea0286048-6k_kazia.htm | 0001213900-26-043086 |
| Document: 0001213900-26-043086-index-headers.html | 0001213900-26-043086 |
| Document: 0001213900-26-043086-index.html | 0001213900-26-043086 |
| Document: 0001213900-26-043086.txt | 0001213900-26-043086 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | SC 13G/A | $9.27 | awaiting T+20 | — | $7.87 (−15.10%) |
Sep 22, 2026 4w ago | 6-K | $10.92 $7.88 | ▼ −27.84% | ▼ −27.28% | $7.87 (−27.93%) |
Sep 1, 2026 7w ago | 6-K | $12.61 $9.60 | ▼ −23.91% | ▼ −23.58% | $7.87 (−37.59%) |
Aug 31, 2026 7w ago | Press Release | $12.63 $9.60 | ▲ +24.03% | ▲ +24.35% | $7.87 (+37.69%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▼ −29.19% | ▼ −29.01% | $7.87 (−42.85%) |
Aug 31, 2026 8w ago | 6-K | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 31, 2026 8w ago | 424B5 | $13.77 $9.75 | ▲ +29.19% | ▲ +29.01% | $7.87 (+42.85%) |
Aug 28, 2026 8w ago | 6-K / 424B5 | $13.58 $9.60 | ▲ +29.31% | ▲ +29.57% | $7.87 (+42.05%) |
Aug 28, 2026 8w ago | 424B5 | $13.58 $9.60 | ▼ −29.31% | ▼ −29.57% | $7.87 (−42.05%) |
Jul 28, 2026 12w ago | 6-K | $12.69 $13.79 | ▲ +8.67% | ▲ +5.29% | $7.87 (−37.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers